Walleye Capital’s C4 Therapeutics CCCC Stock Holding History

Walleye Capital’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$629K	Sell	239,118 -204,223	-46%	-$481K	﹤0.01%	2478
2025 Q4	$847K	Buy	+443,341	New	+$1.05M	﹤0.01%	2577
2025 Q1	–	Sell	-40,819	Closed	-$147K	–	4318
2024 Q4	$147K	Buy	+40,819	New	+$203K	﹤0.01%	3938
2024 Q3	–	Sell	-39,976	Closed	-$185K	–	5335
2024 Q2	$185K	Sell	39,976 -12,328	-24%	-$73.5K	﹤0.01%	4364
2024 Q1	$427K	Buy	+52,304	New	+$405K	﹤0.01%	3335
2023 Q2	–	Sell	-29,792	Closed	-$93.5K	–	4365
2023 Q1	$93.5K	Sell	29,792 -12,945	-30%	-$76.2K	﹤0.01%	2968
2022 Q4	$252K	Sell	42,737 -67,873	-61%	-$563K	﹤0.01%	1899
2022 Q3	$970K	Sell	110,610 -203,656	-65%	-$2.11M	0.02%	996
2022 Q2	$2.37M	Buy	+314,266	New	+$2.77M	0.07%	315
2022 Q1	–	Sell	-81,720	Closed	-$2.63M	–	2314
2021 Q4	$2.63M	Buy	+81,720	New	+$3.23M	0.08%	265

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's CCCC Position: Q1 2026 in Review

Walleye Capital reduced its C4 Therapeutics (CCCC) stake by 46% in Q1 2026, selling an estimated $481K and leaving 239,118 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #2478.

Walleye Capital first reported a position in CCCC in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.63M in Q4 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Walleye Capital held 239,118 shares of C4 Therapeutics worth $629K as of Q1 2026.
Walleye Capital sold 204,223 C4 Therapeutics shares in Q1 2026, an estimated $481K.
C4 Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2478 holding.
Walleye Capital first reported a position in C4 Therapeutics in Q4 2021 and has held it in 10 quarters since.
Walleye Capital's C4 Therapeutics position peaked at $2.63M in Q4 2021.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.